NSABP B-56-I
NSABP B-56-I
A Randomized, Placebo-Controlled, Double Blind Phase 3 Study Evaluating the Safety and Efficacy of the Addition of Velaparib Plus Carboplatin versus the Addition of Carobplatin to Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (Abbvie) Global Accrual = 634
Patient Population:
Patients with early-stage triple-negative breast cancer
Target Accrual: 16 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT02032277
A Randomized, Placebo-Controlled, Double Blind Phase 3 Study Evaluating the Safety and Efficacy of the Addition of Velaparib Plus Carboplatin versus the Addition of Carobplatin to Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (Abbvie) Global Accrual = 634
Patient Population:
Patients with early-stage triple-negative breast cancer
Target Accrual: 16 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT02032277